FDA’s John Jenkins retires after 15 years leading the OND, Teva’s generics CEO Olafsson exits with Actavis’ transition still on the agenda, and Deborah…

Horizon Pharma’s Actimmune has missed the primary endpoint in a phase 3 trial, sparking a 20% drop in its stock price.

In our EuroBiotech roundup this week, Genfit linked to M&A chatter, Pfizer backs premature ejaculation biotech, immunotherapy startup bags cash and more.

Armed with debut financing of $44.5 million, Cambridge-based startup TCR2 Therapeutics is poised to advance its cell-based cancer therapies toward the clinic.

The European Medicines Agency has accepted Regeneron and Sanofi’s dupilumab for review.

Shares in Voyager Therapeutics jumped 35% in after-hours trading on the back of interim data from an early trial of its Parkinson’s disease gene therapy.

Allaying concerns from some quarters that it wouldn’t be passed this year, and coming just one month after the presidential election, the 21st Century Cures…

Nordic Nanovector has raised $60 million to test its CD37-targeting antibody-radionuclide conjugate in combination with rituximab.